Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results

Alexander Roth; Wilma Barcellini; Shirley D'Sa; Yoshitaka Miyakawa; Catherine M Broome; Marc Michel; David J Kuter; Bernd Jilma; Tor Henrik Anderson Tvedt; Ilene C Weitz; Parija Patel; Xiaoyu Jiang; Caroline Reuter; Jun Su; Frank Shafer; Michelle Lee; Sigbjorn Berentsen

doi:10.3324/haematol.2021.279812

Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results

Haematologica. 2022 Jul 1;107(7):1698-1702. doi: 10.3324/haematol.2021.279812.

Authors

Alexander Roth¹, Wilma Barcellini², Shirley D'Sa³, Yoshitaka Miyakawa⁴, Catherine M Broome⁵, Marc Michel⁶, David J Kuter⁷, Bernd Jilma⁸, Tor Henrik Anderson Tvedt⁹, Ilene C Weitz¹⁰, Parija Patel¹¹, Xiaoyu Jiang¹¹, Caroline Reuter¹¹, Jun Su¹¹, Frank Shafer¹¹, Michelle Lee¹¹, Sigbjorn Berentsen¹²

Affiliations

¹ Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen. [email protected].
² Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan.
³ UCLH Centre for Waldenstrom's Macroglobulinemia and Related Conditions, University College London Hospitals NHS Foundation Trust, London.
⁴ Thrombosis and Hemostasis Center, Saitama Medical University Hospital, Saitama.
⁵ Division of Hematology, MedStar Georgetown University Hospital, Washington.
⁶ Henri-Mondor University Hospital, Assistance Publique-Hopitaux de Paris, UPEC, Creteil.
⁷ Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston.
⁸ Department of Clinical Pharmacology, Medical University of Vienna, Vienna.
⁹ Section for Hematology, Department of Medicine, Haukeland University Hospital, Bergen.
¹⁰ Keck School of Medicine of USC, Los Angeles, CA.
¹¹ Sanofi, Cambridge.
¹² Department of Research and Innovation, Haugesund Hospital, Haugesund.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anemia, Hemolytic, Autoimmune* / drug therapy
Antibodies, Monoclonal, Humanized
Complement C1s*
Follow-Up Studies
Humans

Substances

Antibodies, Monoclonal, Humanized
Complement C1s
sutimlimab

Grants and funding

Funding: This study was funded by Sanofi (Waltham, MA, USA). Medical writing and editing support were provided by Rhutika Dessai and Santo D’Angelo of Fishawack Communications Ltd., part of Fishawack Health, and by Lisa Buttle and Sally Ratcliffe of Lucid Group, and funded by Sanofi.